syndrome (AIDS). The major structural and enzymatic proteins of the HIV-1 virus are coded by the gag, pol and env genes. One of the gene products of this virus is a dimeric aspartyl protease that specifically cleaves the precursor forms of the dominant structural and enzymatic proteins to yield mature proteins required to produce infectious virionslf2). An active viral protease is essential for the processing, assembly and maturation of infectious viral particles for HIV-1 1 2) and is therefore an appealing target for therapeutic intervention.
To facilitate the discovery of novel inhibitory compounds, an assay to screen microbial metabolites for inhibitors of HIV-1 protease activity was developed. L-696,474 was found in extracts of Hypoxylon fragiforme (MF5511; ATCC20995). The IC50 of the purified inhibitor, which is a novel cytochalasin, is å 3 jJM and the mode of inhibition is competitive with respect to substrate.
Materials and Methods Methods

Fermentation
The identification and fermentation of the culture that produced L-696,474 was performed as described i accompanying paper3).
Isolation of L-696,474
The isolation and structure determination of L-696,474 was performed as described in an accompanying paper4).
Cloning, Expression and Purification of the HIV-1 Protease Cloning, expression and purification of the HIV-1 protease was performed as described5). The peptide substrate Val-Ser-Gln-Asn-^naphthylAla-Pro-Ile-Val-Gln-Gly-Arg-Arg was synthesized according to the procedure ofMerrifield6). The peptide was labeled with [3H]acetic anhydride by dissolving the peptide (20mg) in 1.5 ml of dimethylformamide. Dimethyl sulfoxide (0.5 ml) was added to clarify the solution. iV-Methyl morpholine (2mol per mol of peptide) was added to the peptide solution and the resulting mixture was added to the [3H]acetic anhydride and allowed to react for 16 hours at room temperature. The labeled peptide was purified to homogeneity with reverse phase C18 chromatography and elution with acetonitrile and the purity was confirmed by reverse phase HPLC.
Assay of HIV-1 Protease Activity
Fermentation broth extracts were mixed with 1.05 fiM [3H]acetyl-Val-Ser-Gln-Asn-/?-naphthylAla-ProIle-Val-Gln-Gly-Arg-Arg and 2 nM HIV-1 protease in final volume of 100 //I containing 100mMsodium acetate buffer, pH 5.5 and 0.05% bovine serum albumin (BSA). After 60 minutes at 37°C the reaction was stopped with 100^1 of5% H3PO4and 150/^1 of the reaction mixture was loaded onto a 1.0ml column of Dowex AG50W-X8resin (H+ form). The column was washed with 1.85ml of water and the [3H]acetyl-product was collected into scintillation vials for counting in a liquid scintillation counter.
Labeling of /?-Casein Fifty mg of /?-casein was dissolved in 5.0ml of 40him sodium phosphate buffer, pH 7.0. Ten ml of formaldehyde was added, the solution was stirred briefly and kept at room temperature for 20 minutes. Sodium borotritide (12.5 mCi) was added and the solution was stirred as before. The solution was dialysed overnight at 4°C against 40mMsodium phosphate buffer pH 7.0 with 3 changes (1 liter each) of buffer. The labeled protein had a specific activity of 3~7 x 106cpm/mg protein and was used as a substrate in the pepsin and stromelysin assays.
Assay of Pepsin Activity Pepsin activity was assayed by incubating pepsin (5 nM) with [3H]/?-casein (2/iM) in 100mMHC1 for 30 minutes at 37°C. The reaction was stopped with 10%TCAand TCA-insoluble material was removed by centrifugation. An aliquot of the TCA-soluble supernatant was transferred to scintillation vials for counting in a liquid scintillation counter.
Assay of Papain and Human Leucocyte Elastase (HLE) Activity
Papain and HLEactivity were assayed as described by Barrett and Kirschke7) and Zimmermanet al. 8).
Assay of Stromelysin Activity Stromelysin activity was assayed by incubating stromelysin (1 0 nM), isolated from gingival fibroblasts9), with [3H]£-casein (2jim) in 100mM HEPES, 10mMCaCl2 and0.05% Brij 35, pH 6.5 for 60minutes at 37°C. The reaction was stopped with 100 /il 4.2% TCAand TCA-insoluble material was removed by centrifugation. An aliquot of the TCA-soluble supernatant was transferred to scintillation vials for counting in a liquid scintillation counter.
Materials
Sodium [3H]borohydride and [3H]acetic anhydride were obtained from NewEngland Nuclear (Boston, MA). /2-Casein, BSA, pepsin, calcium chloride and Brij 35 were obtained from Sigma (St. Louis, MO). DMSO, dimethylformamide and TV-methyl morpholine were obtained from Aldrich Chemical Co. (Milwaukee, WI). Acetonitrile, methanol, sodium acetate, phosphoric acid, trichloroacetic acid, formaldehyde, sodium phosphate and disposable columns were obtained from Fisher (Somerset, NJ). Dowex AG50W-X8 resin (H+ form) was obtained from BioRad (Richmond, CA). HEPES was from Boehringher (Indianapolis, IN). All other reagents were of the highest grade possible.
Results and Discussion
The HIV-1 protease cleaves peptides with sequences representing cleavage sites found in the gag and gag-pol gene products10). The peptide Val-Ser-Gln-Asn-/?-naphthylAla-Pro-Ile-Val is a substrate for the HIV-1 protease and the scissile bond is flanked by the /?-naphthylalanine and proline residues10'11}. The assay described above used the substrate [3H]acetyl-Val-Ser-Gln-Asn-j8-naphthylAla-Pro-Ile-Val-Gly-ArgArg. The arginine residues allow this substrate to bind tightly to the H+form of DowexAG50-X8resin and this facilitates the separation of the labeled peptide from the unhydrolyzed substrate and the other product peptide. HIV-1 protease activity was linear with respect to time (up to 120 minutes), substrate and enzyme concentrations (results not shown). Less than 10%of the substrate was hydrolyzed during the incubation period. Also, the resin used to separate the labeled product peptide from unhydrolyzed substrate bound 99.8% of the substrate (results not shown). A fungal culture (MF551 1, ATCC20995) produced L-696,474 that inhibited HIV-1 protease activity.
L-696,474 is a unique cytochalasin with a molecular weight of477 and an empirical formula of C3oH39N04 (Fig. 1) . L-696,474 reduced HIV-1 protease activity in a dose-dependent manner (Fig. 2) with an IC50 of HIV-1 protease assays were performed in the presence of L-696,474, L-696,475 or L-697,318 at the indicated concentrations. After 60 minutes at 37°C the assays were stopped and processed as described in the Whenenzymeactivity was measured as a function of the HIV-1 protease concentration in the presence of various concentrations of L-696,474 the data presented in Fig. 5 were obtained. As expected, increasing concentrations of HIV-1 protease (in the absence of inhibitor) produced a linear increase in the amount of product formed. Increasing amounts of L-696,474 decreased product formation. The HIV-1 protease activity in the presence of L-696,474 was proportional to the enzyme concentration, but the slopes of the lines (in the presence of L-696,474) were less than in the absence of inhibitor. The percent inhibition (due to L-696,474) was the same at any concentration of enzymeand depended entirely upon the concentration of the inhibitor since the substrate concentration was constant. This, as well as the fact that the curves all intersect at the origin also supports the premise that L-696,474 is a competitive inhibitor12).
The HIV-1 protease is a 99-amino acid aspartyl acid protease1>2). To determine whether L-696,474 was specific for the HIV-1 protease L-696,474 was tested against pepsin, stromelysin, papain and human The assays were stopped and processed as described in the Methodssection.
HIV-1 protease assays were performed at the indicated HIV-1 protease and L-696,474 concentrations. The 3H-substrate concentration was 1.05 /im. After 60 minutes at 37°C the assays were stopped and processed as described in the Methods section.
leucocyte elastase and was found to be inactive against stromelysin, papain and human leucocyte elastase (results not shown). L-696,474 inhibited pepsin activity with an IC50 of 52/um. These data suggest that while L-696,474 could inhibit a related aspartyl acid protease it was a more selective inhibitor of the HIV-1 protease.
To establish whether other knowncytochalasins could modulate HIV-1 protease activity, cytochalasins B, C, D, E, F, H and J were tested and found to be inactive (results not shown). Cytochalasin A inhibited HIV-1 protease activity with an IC50 of 3^m and the inhibition was competitive with respect to substrate (P. Darke, personal communication). L-696,474 is similar to cytochalasin H (Fig. 1) , differing by one less hydroxyl group at position C-18, but cytochalasin H had no effect on HIV-1 protease activity. A further indication of the tight structure-activity relationship that exists in this series of compounds is evident from the lack of activity of the closely related isomeric (L-697,318) and the deshydroxy (L-696,475)
forms of L-696,474. Cytochalasin A, which contains a 14-membered lactone ring while L-696,474 contains a ll-membered carbocyclic ring, was as effective in inhibiting the HIV-1 protease as L-696,474. By inspection, the two compounds.are quite dissimilar and activity of either molecule may depend on the relative conformation of these inhibitors at the active site of the protease. The active HIV-1 protease is composed of two monomers, each contributing one of the two conserved aspartates to the active site13 '14) . It is likely that L-696,474 and cytochalasin A inhibit the HIV-1 protease by binding to the dimeric form of the enzyme. The alternative possibility that either compound binds to the monomericform of the enzymeto prevent dimer formation can be discounted since there is no evidence to suggest that, under the conditions of the assay, there is an appreciable amountof the monomericform of the enzyme. Recently, an active single monomericform of the HIV-1protease was developed15). L-696,474 was tested against this form of the HIV-1 protease and found to inhibit the monomeric form of the protease as well as it inhibited the dimeric form of the protease (P. Darke, personal communication). The identification of a novel, nonpeptide, natural product inhibitor of the HIV-1 protease is encouraging in that this, and other, unique and structurally diverse molecules would be useful chemical entities on which to base a medicinal chemistry effort to develop new compoundsthat maybe more efficacious in the treatment and management of AIDS.
